Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2001

View Archived Issues

Thiazolinediones may provide therapeutic benefits in demyelinating diseases

Research grant awarded for isolating potential anticancer agents from mushrooms

Atugen enters evaluation agreement with Byk Gulden

Paradigm and StemCo collaborate on biochemical profiling of adult human stem cells

Bayer enters postgenomics collaboration

AERx iDMS at least as effective as subcutaneous insulin in type 2 diabetics

Antitumor effects of COX-2-specific inhibitor JTE-522 described at Japanese meeting

Exelixis to acquire Genomica

Phase II study initiated for ISIS-104838 in rheumatoid arthritis

Virulizin enters phase III for treatment of pancreatic cancer

Shire acquires license to compound for Parkinson's disease

Oxford GlycoSciences and Teva sign agreement for Vevesca in Israel

Various presentations at Oxygen Society meeting highlight broad-spectrum potential of SOD mimetics

Antisense inhibitor of HCV yields encouraging preliminary results in chronically infected patients

Pharmacokinetic and safety analyses of phase I Heptazyme trial in HCV presented at AASLD

Breakthrough treatment for severe sepsis approved for the first time

Inhibition of IL-6 binding produces clinical improvement in RA

Investigational anti-TNF antibody improves clinical measures of RA and joint destruction

Regeneron proceeds to phase II trials with IL-1 Trap following promising phase I findings

HIV protease inhibitors claimed in recent patent by Pharmacor team

Merck reports new MC4 receptor agonists and potential uses for these compounds

Two Pharmacia patents cover novel antiviral agents particularly useful against herpesviruses

Alcon identifies several related series of antiglaucoma agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...